Cognyte Software Stock Forecast, Price & News

Cognyte Software (NASDAQ:CGNT) Frequently Asked Questions

Is Cognyte Software a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cognyte Software in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cognyte Software stock.
View analyst ratings for Cognyte Software or view top-rated stocks.

How were Cognyte Software's earnings last quarter?

Cognyte Software Ltd. (NASDAQ:CGNT) posted its quarterly earnings data on Monday, December, 20th. The medical device company reported $0.21 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.10 by $0.11. The medical device company earned $118.70 million during the quarter, compared to analysts' expectations of $114.83 million. Cognyte Software had a trailing twelve-month return on equity of 10.53% and a net margin of 0.40%. The company's revenue for the quarter was up 5.0% on a year-over-year basis.
View Cognyte Software's earnings history.

What guidance has Cognyte Software issued on next quarter's earnings?

Cognyte Software issued an update on its FY22 earnings guidance on Tuesday, December, 21st. The company provided earnings per share guidance of $0.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.81. The company issued revenue guidance of $470.4-$489.6 million, compared to the consensus revenue estimate of $489.74 million.

What price target have analysts set for CGNT?

5 brokers have issued 12-month price objectives for Cognyte Software's shares. Their forecasts range from $17.00 to $42.00. On average, they expect Cognyte Software's share price to reach $25.47 in the next twelve months. This suggests a possible upside of 96.2% from the stock's current price.
View analysts' price targets for Cognyte Software or view top-rated stocks among Wall Street analysts.

Who are Cognyte Software's key executives?

Cognyte Software's management team includes the following people:

• Mr. Elad Sharon, CEO & Director (Age 45)
• Mr. David Abadi, Chief Financial Officer (Age 47)
• Mr. Ziv Levi, Chief Legal Officer (Age 52)
• Ms. Amit Daniel, Chief Marketing Officer (Age 49)
• Ms. Rini Karlin, Chief People Officer (Age 49)
• Mr. Miki Migdal, Chief Bus. Officer (Age 60)
• Mr. Marom Ben Menahem, Chief Revenue Officer (Age 50)
• Mr. Sharon Chouli, Chief Customer Officer (Age 51)

Who are some of Cognyte Software's key competitors?

Some companies that are related to Cognyte Software include Engagesmart (ESMT), Sprinklr (CXM), Matterport (MTTR), Commvault Systems (CVLT), Coursera (COUR), Tuya (TUYA), Kingsoft Cloud (KC), Cerence (CRNC), PowerSchool (PWSC), PagerDuty (PD), Bottomline Technologies (de) (EPAY), 3D Systems (DDD), EverCommerce (EVCM), SEMrush (SEMR) and JFrog (FROG).
View all of CGNT's competitors.

What other stocks do shareholders of Cognyte Software own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cognyte Software investors own include EndoChoice (GI), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Fc Global Realty (FCRE), Galectin Therapeutics (GALT), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), Neurocrine Biosciences (NBIX) and Nymox Pharmaceutical (NYMX).

What is Cognyte Software's stock symbol?

Cognyte Software trades on the NASDAQ under the ticker symbol "CGNT."

Who are Cognyte Software's major shareholders?

Cognyte Software's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Poehling Capital Management LLC (0.05%).
View institutional ownership trends for Cognyte Software.

Which major investors are selling Cognyte Software stock?

CGNT stock was sold by a variety of institutional investors in the last quarter, including Poehling Capital Management LLC.
View insider buying and selling activity for Cognyte Software or view top insider-selling stocks.

How do I buy shares of Cognyte Software?

Shares of CGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cognyte Software's stock price today?

One share of CGNT stock can currently be purchased for approximately $12.98.

How much money does Cognyte Software make?

Cognyte Software has a market capitalization of $856.55 million and generates $443.46 million in revenue each year. The medical device company earns $14.20 million in net income (profit) each year or $0.03 on an earnings per share basis.

How many employees does Cognyte Software have?

Cognyte Software employs 2,000 workers across the globe.

What is Cognyte Software's official website?

The official website for Cognyte Software is www.cogentixmedical.com.

Where are Cognyte Software's headquarters?

Cognyte Software is headquartered at 5420 FELTL ROAD, MINNETONKA MN, 55343.

How can I contact Cognyte Software?

Cognyte Software's mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 972-9962-2300 or via email at [email protected].